[Pharmacokinetics study of intraperitoneal carboplatin in gynecologic carcinoma].
Twenty patients with surgically and pathologically confirmed gynecologic cancer from December, 1991 to December, 1992 were treated by intraperitoneal (i.p.) chemotherapy with carboplatin in 15 and by intravenous (i.v.) chemotherapy with carboplatin in 5, patients had normal hepatic and renal function test and were nonsmoker. Using Grathite atomic absorption spectrum method, total mean maximal plasmic carboplatin concentration in the cases by intravenous infusion was 8 times greater than those by intraperitoneal infusion. The half-life of plasmic elimination in the cases treated by i.v. infusion and by i.p. infusion were respectively 10.82 +/- 4.95 hours and 54.04 +/- 10.75 hours (P < 0.05). But total carboplatin plasmic clearance in the cases were 1.88 +/- 0.53 ml/min and 1.12 +/- 0.58 ml/min, respectively (P < 0.05). Pharmacokinetic profiles suggest a possible therapeutic advantage by giving the drug intraperitoneally for the treatment of tumour nodules situated in the peritoneum. This research also suggest the method has the possibility in increasing antitumn effect and decreasing bone marrow in intoxication because of the wide distribution, low plasmic concentration and slow clearance of drugs.